0001275187 2025-06-01 2026-05-31 0001275187 2025-11-30 0001275187 2026-09-18 iso4217:USD shares 10-K/A true 2026-05-31 --05-31 2026 false 0-50761 AngioDynamics, Inc. DE 11-3146460 14 Plaza Drive Latham NY 12110 518 795-1400 Common Stock, par value $.01 per share ANGO NASDAQ Global Select Market ANGO NASDAQ No No Yes Yes Accelerated Filer false false true false false 436293219 42054450 Deloitte & Touche LLP Boston, Massachusetts 34 <div style="text-indent: 23.4pt; color: rgb(24, 24, 24);">The Compensation and Human Capital Committee approves all equity awards granted to our NEOs and Board on or before the grant date.  <span style="color: rgb(0, 0, 0);">Annual equity awards are generally granted effective after our applicable fiscal year-end earnings release following the decision to make the grant, regardless of the timing of the decision.  Our Compensation and Human Capital Committee has elected to grant equity-based awards shortly following our earnings releases so that the equity-based awards are granted (and valued) at a point in time when the most important information about our company then known to management and our board is likely to have been disseminated in the market.  The Compensation and Human Capital Committee may also grant equity awards at other times during the year due to special circumstances, including to new executive officers upon hire or promotion or a change in an executive officer’s role.  As a matter of good corporate governance, we do not grant equity awards in anticipation of the release of material nonpublic information and, in any event, we do not time the release of material nonpublic information in coordination with grants of equity awards in a manner that intentionally benefits our NEOs or directors. </span> The Compensation and Human Capital Committee did not take material nonpublic information into account when determining the timing and terms of equity awards in fiscal year 2026.</div> Annual equity awards are generally granted effective after our applicable fiscal year-end earnings release following the decision to make the grant, regardless of the timing of the decision.  Our Compensation and Human Capital Committee has elected to grant equity-based awards shortly following our earnings releases so that the equity-based awards are granted (and valued) at a point in time when the most important information about our company then known to management and our board is likely to have been disseminated in the market.  The Compensation and Human Capital Committee may also grant equity awards at other times during the year due to special circumstances, including to new executive officers upon hire or promotion or a change in an executive officer’s role. true As a matter of good corporate governance, we do not grant equity awards in anticipation of the release of material nonpublic information and, in any event, we do not time the release of material nonpublic information in coordination with grants of equity awards in a manner that intentionally benefits our NEOs or directors. true false true 0001275187 false FY